

Shaun Chou

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9203779/publications.pdf>

Version: 2024-02-01

29
papers

974
citations

567281

15
h-index

501196

28
g-index

30
all docs

30
docs citations

30
times ranked

1257
citing authors

#	ARTICLE	IF	CITATIONS
1	Mass Forming Basement Membrane Material Secondary to Adnexal Adenocarcinoma - a Case Report. International Journal of Surgical Pathology, 2022, , 106689692210869.	0.8	0
2	Merkel cell carcinoma in situ: A systematic review of prognosis and management. Australasian Journal of Dermatology, 2022, 63, .	0.7	4
3	Duodenal plasma cells correspond to serum IgA in common variable immunodeficiency. Pathology, 2021, 53, 503-507.	0.6	0
4	Successful treatment of highly refractory necrobiotic xanthogranuloma with peginterferon alfa-2a. Clinical and Experimental Dermatology, 2021, 46, 731-733.	1.3	2
5	Survival and prognosis of individuals receiving programmed cell death 1 inhibitor with and without immunologic cutaneous adverse events. Journal of the American Academy of Dermatology, 2020, 82, 311-316.	1.2	55
6	Cutaneous adverse events of anti-programmed death 1 antibodies combined with anti-cytotoxic T-lymphocyte-associated protein 4 therapy use in patients with metastatic melanoma. Melanoma Research, 2019, 29, 172-177.	1.2	15
7	Vitiligo-like depigmentation in oncology patients treated with immunotherapies for nonmelanoma metastatic cancers. Clinical and Experimental Dermatology, 2019, 44, 643-646.	1.3	36
8	Naevus lightening in melanoma patients under <scp>BRAF</scp>/<scp>MEK</scp> inhibitor combination therapy versus checkpoint immunotherapy: A histological and immunohistochemistry analysis. Pigment Cell and Melanoma Research, 2018, 31, 341-344.	3.3	1
9	Anti-programmed cell death-1 therapy-associated bullous disorders: a systematic review of the literature. Melanoma Research, 2018, 28, 491-501.	1.2	19
10	Incidence of Basal Cell Carcinoma and Squamous Cell Carcinoma in Patients on Antiprogrammed Cell Death-1 Therapy for Metastatic Melanoma. Journal of Immunotherapy, 2018, 41, 343-349.	2.4	9
11	Parathyroid Frozen Section Interpretation via Desktop Telepathology Systems: A Validation Study. Journal of Pathology Informatics, 2018, 9, 41.	1.7	3
12	Cutaneous Nodules in the Genital Area in a Patient With Chronic Graft-vs-Host Disease. JAMA Dermatology, 2017, 153, 465.	4.1	1
13	Histologic Assessment of Lichenoid Dermatitis Observed in Patients With Advanced Malignancies on Antiprogrammed Cell Death-1 (anti-PD-1) Therapy With or Without Ipilimumab. American Journal of Dermatopathology, 2017, 39, 23-27.	0.6	28
14	PD-1 inhibitor-associated lichenoid inflammation with incidental suprabasilar acantholysis or vesiculation—Report of 4 cases. Journal of Cutaneous Pathology, 2017, 44, 851-856.	1.3	21
15	Acute Truncal Lymphedema Secondary to Axillary Metastatic Melanoma Presenting Like Cellulitis. Case Reports in Medicine, 2017, 2017, 1-3.	0.7	2
16	Intracorneal pustular drug eruption, a novel cutaneous adverse event in anti-programmed cell death-1 patients that highlights the effect of anti-programmed cell death-1 in neutrophils. Melanoma Research, 2017, 27, 641-644.	1.2	14
17	Bullous pemphigoid, an autoantibody-mediated disease, is a novel immune-related adverse event in patients treated with anti-programmed cell death 1 antibodies. Melanoma Research, 2016, 26, 413-416.	1.2	75
18	PD-1 inhibitors induced bullous lichen planus-like reactions: a rare presentation and report of three cases. Melanoma Research, 2016, 26, 421-424.	1.2	40

#	ARTICLE	IF	CITATIONS
19	Cutaneous adverse events (AEs) of anti-programmed cell death (PD)-1 therapy in patients with metastatic melanoma: A single-institution cohort. <i>Journal of the American Academy of Dermatology</i> , 2016, 74, 455-461.e1.	1.2	247
20	Predicting discordant HER2 results in ipsilateral synchronous invasive breast carcinomas: experience from a single institution. <i>Pathology</i> , 2015, 47, 637-640.	0.6	3
21	A case of bullous pemphigoid in a patient with metastatic melanoma treated with pembrolizumab. <i>Melanoma Research</i> , 2015, 25, 265-268.	1.2	116
22	Factors influencing the development of cutaneous squamous cell carcinoma in patients on BRAF inhibitor therapy. <i>Journal of the American Academy of Dermatology</i> , 2015, 72, 809-815.e1.	1.2	39
23	Cutaneous Toxic Effects of BRAF Inhibitors Alone and in Combination With MEK Inhibitors for Metastatic Melanoma. <i>JAMA Dermatology</i> , 2015, 151, 1103.	4.1	139
24	Panniculitis in Patients Treated With BRAF Inhibitors. <i>American Journal of Dermatopathology</i> , 2014, 36, 493-497.	0.6	52
25	High concordance rate of HER2 status assessed via silver in situ hybridisation (SISH) between core biopsy and excision specimens: a 4 year retrospective review from a single institution. <i>Pathology</i> , 2014, 46, 240-241.	0.6	2
26	Dabrafenib-associated necrobiotic granulomatous reaction. <i>Australasian Journal of Dermatology</i> , 2014, 55, 306-308.	0.7	8
27	Renal Anastomosing Hemangiomas With a Diverse Morphologic Spectrum. <i>International Journal of Surgical Pathology</i> , 2014, 22, 369-373.	0.8	22
28	Fine-needle aspiration cytology features of a recurring plexiform fibrohistiocytic tumor in the upper limb and review of the literature. <i>Diagnostic Cytopathology</i> , 2011, 39, 49-53.	1.0	3
29	Extraventricular neurocytoma with atypical features and ganglionic differentiation. <i>Journal of Clinical Neuroscience</i> , 2010, 17, 920-922.	1.5	17